Find a study
Studies of GLP-1, incretin, and related peptide medications for weight and metabolic health.
3 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- Obesity / overweightHigh blood pressureCOPD (chronic lung disease)
Feasibility of Semaglutide in Advanced Lung Disease
Testing whether semaglutide can be given safely to people with advanced lung disease
📍 University of Pennsylvania Perelman School of Medicine · Philadelphia, PA · Get directions →
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1.
- Dementia / Alzheimer's
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
Testing a treatment with IL-2 and semaglutide in people with Alzheimer's
📍 Houston Methodist Research Institute · Houston, TX · Get directions →
Alzheimer's disease (AD) is the most common cause of dementia. Despite major research efforts, effective treatments that slow or stop disease progression remain limited.
- Crohn's / ulcerative colitis (IBD)
Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients
Testing diet plus an injectable medicine to treat mild Crohn’s in people with higher BMI
📍 University of Miami · Miami, FL · Get directions →
The purpose of this study is to use diet and an injectable medication called tirzepatide (Zepbound) glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GIP-GLP-1 RA) medication as adjunctive therapy (another treatment used together with the primary treatment) for Crohn's disease patients with mild disease who are on stable doses of biologic medication (infliximab or adalimumab) and who have a body mass index (BMI) of at least 27.